Prenatal Immunomodulation: Reassessing the Safety of MS Therapies
A large-scale historical cohort study from Israel provides critical long-term data on the safety of prenatal exposure to disease-modifying therapies (DMTs) for multiple sclerosis. The research, published in Clinical Pharmacology & Therapeutics, analyzed outcomes for over 1,300 children born to mothers with MS, with a subset exposed to various DMTs including interferons, glatiramer acetate, monoclonal antibodies, and newer agents like sphingosine-1-phosphate receptor (S1PR) modulators. Over a mean follow-up of 7.5 years, the study found no significant association between prenatal DMT exposure and an increased risk of neurodevelopmental disorders in the offspring. However, a signal emerged for a specific class of drugs: exposure to S1PR modulators was associated with a higher, though statistically uncertain due to small sample size, rate of major congenital anomalies.
Why it might matter to you: This study directly addresses a key gap in the immunology and pharmacology of pregnancy, offering evidence that can inform clinical guidelines and shared decision-making. For immunologists and clinicians managing autoimmune conditions, the data provide reassurance on the neurodevelopmental safety of most DMTs but highlight a potential risk profile for S1PR modulators that warrants further investigation. This real-world evidence is crucial for optimizing treatment algorithms that balance maternal disease control against fetal safety, a core consideration in reproductive immunology.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
